JG
MRNS

Jefferies Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Jefferies Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3.29M Hold
494,764
– – 0.03% 449
2022
Q2 		$2.39M Hold
494,764
– – 0.02% 553
2022
Q1 		$4.63M Buy
494,764
+55,000
+13% +$546K 0.03% 442
2021
Q4 		$5.22M Hold
439,764
– – 0.03% 440
2021
Q3 		$5M Buy
439,764
+424,467
+2,775% +$5.84M 0.04% 434
2021
Q2 		$274K Buy
+15,297
New +$246K ﹤0.01% 1325
2020
Q4 		– Sell
-508,423
Closed -$6.53M – 1861
2020
Q3 		$6.53M Buy
508,423
+725
+0.1% +$6.26K 0.07% 229
2020
Q2 		$5.16K Buy
507,698
+34,673
+7% +$319K 0.06% 269
2020
Q1 		$3.84M Buy
+473,025
New +$4.1M 0.04% 409
2019
Q1 		– Sell
-425,000
Closed -$4.88M – 2714
2018
Q4 		$4.88M Buy
+425,000
New +$8.6M 0.04% 425
2018
Q2 		– Sell
-6,225
Closed -$95K – 2761
2018
Q1 		$95K Buy
+6,225
New +$148K ﹤0.01% 2069

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Jefferies Group's MRNS Position: Q3 2022 in Review

Jefferies Group held its Marinus Pharmaceuticals, Inc (MRNS) position steady in Q3 2022 at 494,764 shares worth $3.29M. The position accounts for 0.03% of the portfolio, ranked #449.

Jefferies Group first reported a position in MRNS in Q1 2018 and has held it in 11 quarters since. The position peaked at $6.53M in Q3 2020. 69 funds tracked by Wall St. Rank hold MRNS as of Q3 2022.

  • Jefferies Group held 494,764 shares of Marinus Pharmaceuticals, Inc worth $3.29M as of Q3 2022.
  • Jefferies Group left its Marinus Pharmaceuticals, Inc share count unchanged in Q3 2022.
  • Marinus Pharmaceuticals, Inc made up 0.03% of Jefferies Group's portfolio in Q3 2022, its #449 holding.
  • Jefferies Group first reported a position in Marinus Pharmaceuticals, Inc in Q1 2018 and has held it in 11 quarters since.
  • Jefferies Group's Marinus Pharmaceuticals, Inc position peaked at $6.53M in Q3 2020.
  • 69 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.